Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-22-015548
Filing Date
2022-04-22
Accepted
2022-04-22 16:02:24
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A edge20003258x2_defa14a.htm DEFA14A 8967
2 edge20003258x2_nc01.jpg GRAPHIC 700313
3 edge20003258x2_nc02.jpg GRAPHIC 399010
  Complete submission text file 0001140361-22-015548.txt   1484222
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40366 | Film No.: 22845445
SIC: 2834 Pharmaceutical Preparations